SAB Biotherapeutics, Inc.

91 articles with SAB Biotherapeutics, Inc.

• SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor ConferenceConference to take place Feb. 6-9 in New York

  1/19/2023

  SAB Biotherapeutics announced that Eddie Sullivan, PhD, co-founder, President and CEO of SAB Biotherapeutics, will present at the 2023 BIO CEO & Investor Conference on Monday, February 6 at 11:15am ET.

• SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract

  1/18/2023

  SAB Biotherapeutics announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research.

• SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes

  1/10/2023

  SAB Biotherapeutics today announced the successful completion of an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic as a way to prevent and/or delay onset and progression of type 1 diabetes (T1D) and potentially other T-cell mediated autoimmune diseases.

• SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase

  1/9/2023

  SAB Biotherapeutics announced today that Alexandra Kropotova, MD, Executive Vice President and Chief Medical Officer, will deliver a presentation at the Biotech Showcase in San Francisco on Tuesday, Jan. 10 at 2:30 p.m. PST.

• SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

  1/5/2023

  SAB Biotherapeutics (Nasdaq: SABS) announced today results from a project in collaboration with global biotechnology leader CSL (ASX: CSL), confirming that SAB’s DiversitAb™ platform can generate functional fully-human anti-idiotype polyclonal antibodies that can effectively target and neutralize autoantibodies associated with autoimmune diseases.

• SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco

  12/15/2022

  SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that SAB Biotherapeutics has been selected to present at the Biotech Showcase 2023 meeting.

• SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

  12/7/2022

  The Warrants will be exercisable beginning six-months from the date of issuance and will be exercisable, in whole or in part, at an exercise price of $1.08 per share.

• SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

  11/21/2022

  SAB Biotherapeutics today announced SAB-142 is being progressed as a therapeutic agent to prevent and/or delay onset and progression of Type 1 diabetes (T1D) and potentially other T-cell mediated autoimmune diseases.

• SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results

  11/15/2022

  SAB Biotherapeutics today reported financial results for the third quarter ended September 30, 2022, and provided a company update.

• SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022

  11/8/2022

  SAB Biotherapeutics today announced the company will be attending and presenting at this year’s U.S. Pharma Partnering Summit, being held on Nov. 17-18 in Boston, MA.

• SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference

  11/3/2022

  SAB Biotherapeutics announced that the Company presented an overview of its DiversitAb™ polyclonal platform and data on SAB-176 and SAB-185 showing the benefits of fully-human polyclonal antibodies derived from SAB’s Transchromosomic Bovine™ over plasma derived antibodies from humans, at the 2022 Plasma Product Biotechnology Conference in Limassol, Cyprus, which concluded on Nov. 3.

• SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions

  10/27/2022

  SAB Biotherapeutics today announced the company has entered into an exclusive manufacturing services agreement with Emergent BioSolutions Inc. (NYSE: EBS).

• SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza

  9/28/2022

  SAB Biotherapeutics released today new data presented at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases.

• SAB Biotherapeutics to Present New Data at ISIRV OPTIONS XI Conference on SAB-176 Phase 2a Influenza Trial and SAB-185’s Effectiveness Against Multiple COVID-19 Variants

  9/23/2022

  SAB Biotherapeutics announced today that the Company will present new data on its fully-human polyclonal antibody platform’s ability to maintain its efficacy against multiple variants of several highly mutating viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from Sept. 26-29, 2022.

• SAB Biotherapeutics Provides Company Update for Q2 2022 Financial ResultsExpects cash is sufficient to fund operations for the forward twelve months

  8/10/2022

  SAB Biotherapeutics today reported financial results for the second quarter ended June 30, 2022 and provided a company update.

• SAB Biotherapeutics Advancing Pipeline and Expands into Treatment for C. Diff. as DoD Contract Winds Down

  8/9/2022

  SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, announced that it will be discontinuing its work with the U.S. Department of Defense under a prototype research and development agreement.

• SAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update

  8/4/2022

  SAB Biotherapeutics today announced that it will host a Virtual 2022 Annual R&D Portfolio Update on Wednesday, August 17, 2022, at 10:30 a.m. ET.

• SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors

  7/11/2022

  SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced the appointment of Rear Admiral (RADM), retired, Scott Giberson, a former Assistant U.S. Surgeon General and two-star admiral with the U.S. Public Health Service to SAB’s Board of Directors.

• SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer

  6/6/2022

  SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced the appointment of Alexandra Kropotova, M.D., as Chief Medical Officer (CMO).

• SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit

  5/31/2022

  SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced its participation at the Large Animal Genetic Engineering Summit (LAGE) taking place June 5-8, 2022, in Park City, Utah.